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The MAP kinases, discovered approximately 20 years ago, together with their immediate upstream regulators, are among the most highly
studied signal transduction molecules. This body of work has shaped many aspects of our present views of signal transduction by protein kinases.
The effort expended in this area reflects the extensive participation of these regulatory modules in the control of cell fate decisions, i.e.,
proliferation, differentiation and death, across all eukaryotic phylla and in all tissues of metazoans. The discovery of these kinases is reviewed,
followed by a discussion of some of the features of this signaling module that account for its broad impact on cell function and its enormous
interest to many investigators.
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Building on evidence that insulin and mitogens acted
through novel, possibly covergent mechanisms to promote
intracellular protein phosphorylation [1,2] through the
activation of protein (Ser/Thr) kinases [3,4], Sturgill and
Ray [5] detected an insulin-activated protein (Ser/Thr) kinase
activity in extracts of 3T3-L1 adipocytes, capable of phos-
phorylating a contaminating high molecular weight polypep-
tide identified as microtubule-associated protein-2 (MAP-2).
Partial purification indicated that the kinase, which behaved
as a 35–40 kDa polypeptide, was stably activated by insulin
treatment, and its activation was accompanied by an increase
in 32P incorporation into 32P-Tyr and 32P-Thr residues on a
copurifying 40 kDa polypeptide [6]. The kinase activity also
could be adsorbed by anti-phosphotyrosine antibodies,
confirming the occurrence of tyrosine phosphorylation of
the kinase polypeptide concomitant with its activation [7]. In
addition, the kinase could be deactivated by treatment in vitro⁎ Department of Medicine, Harvard Medical School, 185 Cambridge St.,
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doi:10.1016/j.bbamcr.2006.11.006with either a tyrosine-specific or a serine/threonine-specific
protein phosphatase [8]. Few bona fide regulatory tyrosine
phosphorylations had as yet been identified, apart from those
on various receptor and nonreceptor tyrosine kinases
themselves [9]. Moreover, even in cells expressing constitu-
tively active tyrosine kinases such as vSrc, the absolute
increase in Ser/Thr phosphorylation of cellular proteins
exceeded the increase in Tyrosine phosphorylation by 100–
1000 fold [10]. The possibility that this MAP-2 kinase might
be a ubiquitous effector of mitogenic stimuli was reinforced
by the finding that the MAP-2 kinase polypeptide was
identical to the 41–43 kDa polypeptides [11] characterized
previously whose tyrosine phosphorylation was stimulated by
many polypeptide growth factors [12–15] and by active
phorbol esters [15–17]. This realization prompted the
redesignation of acronym “MAP” from “microtubule-asso-
ciated protein” to “mitogen-activated protein”, and thus the
MAP kinase as it is now known. These features created
intense interest in the MAP kinase; a protein (Ser/Thr) kinase
that was activated by insulin and growth factors through
tyrosine-specific phosphorylation promised to be an important
downstream effector, and perhaps even a direct substrate of
the tyrosine kinases.
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The MAP kinase was not the first insulin-mitogen activated
protein (Ser/Thr) kinase described. Work from several labs had
shown earlier that the Ser/Thr phosphorylation of the ribosomal
protein S6 that occurs in vivo [18–20] as a nearly universal
response to insulin or mitogen stimulation is paralleled by the
appearance of stably activated, 40S-S6 selective protein kinase
activities in extracts prepared from the insulin/mitogen treated
cells [3,4]. The first of these S6 kinases to be purified (now
called Rsks) were from Xenopus oocytes [21,22], and much
evidence indicated that these S6 kinases were activated
downstream of tyrosine kinases, including by the direct
microinjection into oocytes of tyrosine kinase polypeptides
such as vSrc [23], vAbl [24], and the insulin receptor itself [25].
Nevertheless, the Xenopus S6 kinase was activated exclusively
by Ser/Thr phosphorylation, as the insulin -activated S6 kinase
lacked 32P-Tyrosine and its activity was abolished by (Ser/Thr)-
specific phosphatases [26]. Remarkably, the partially purified,
insulin-activated MAP kinase was shown to phosphorylate
directly and activate the purified Xenopus S6 kinase [27].
Independent studies contemporaneously identified a set of
mitogen activated S6 peptide kinases in extracts of EGF-treated
NIH3T3 cells that were themselves activated by upstream,
EGF-regulated kinases [28–30].
The ability of the MAP kinase to activate an S6 kinase
identified what proved to be the first physiologic MAPK
substrate, and represented an important milestone in growth
factor signaling. The concept of a protein kinase cascade,
however was not novel; the first example had been defined by
Krebs and colleagues in the activation of phosphorylase b
kinase by the cyclic AMP-dependent protein kinase [31].
Moreover it was already appreciated that the AMP-activated
protein kinase required phosphorylation by an upstream kinase
(s) [32] whose identities (LKB1, CAMKKβ, TAK1) have been
uncovered only recently [33–35]. The most startling aspect of
the MAPK cascade was revealed by the molecular cloning of a
cDNA encoding the MAPK polypeptide [36]; the primary
sequence of the p44 MAPK (called ERK1) was nearly 50%
identical to the sequences of a pair of then recently described S.
cerevisiae protein kinases KSS1 [37] and FUS3 [38], identified
as participants in the yeast mating pathway. The remarkably
high conservation of structure between these yeast and
mammalian kinase polypeptides across a vast phyllogenetic
distance indicated that the role of this family of protein kinases
as mediators of receptor-regulated cellular differentiation and
proliferation was both ancient and highly conserved. Moreover,
it was known by then that the S. cerevisiae mating pathwayTable 1
MAP4K MAP3K MAP2K
PAK-3 (cRaf-1) ARaf, BRaf cRaf-1, cMos, Tpl2/COT MAP2K1
GCK GCKR HPK1
PAK1/2
MEKK1–4 ASK1, Tpl2/COT TAK1
MLK2/3, DLK
MAP2K4
MEKK3,4 ASK1 TAK2 TAO1/2 MAP2K3
WNK1 MEKK2,3 MP2K5contained at least two other indispensable protein kinases, STE7
and STE11 [39–42] (STE20 was discovered somewhat later;
[43]). Thus an intense effort followed to define the order and
biochemical actions of each of these yeast kinases, as well as the
identity of the upstream activators of the MAPKs evident in
various vertebrate systems. Numerous reports described the
partial purification of a MAPK activator as a cytoplasmic
protein of 50–60 kDa capable of promoting the phosphorylation
of the MAPKs ERK1 and ERK2 in vitro on both Thr and Tyr
residues, accompanied by an increased MAPK catalytic activity
(e.g., [44,45]; reviewed comprehensively in [46]); these
findings eliminated the possibility that the MAPK was the
direct substrate of a tyrosine-specific kinase. The MAPKs are
able to autoactivate slowly in vitro by autophosphorylation; this
property together with the inability of the MAPK activators to
catalyze significant phosphorylation of other polypeptides
created uncertainty as to whether the MAPK activators were
protein kinases. Nevertheless, their ability to phosphorylate
catalytically-inactive mutant MAPK polypeptides resolved this
issue. Designated MAP kinase kinases [MKKs] or MAP and
ERK kinases [MEKs], the primary sequences of MKKs from
various sources, obtained initially as partial peptide sequences
[47–50], and subsequently from cDNAs [51,52], disclosed that
the vertebrate MKKs were 30–40% identical in overall primary
sequence to STE7; two kinases, MKK1 and MKK2, each
capable of activating ERK1 and ERK2, were ultimately
identified. Hereafter, the MAP kinase kinases and their
upstream kinase regulators will be referred to as MAP2Ks,
MAP3Ks and MAP4Ks (Table 1).
Many studies demonstrated that the mammalian MAP2K
activity was itself inactivated by treatment with protein (Ser/
Thr) phosphatase, indicating that at least one additional protein
(Ser/Thr) kinase lay upstream [46]. In S. cerevisiae, the ability
of mating pheromone to induce the dual (Tyr/Thr) phosphor-
ylation of FUS3 was shown to require both the STE7 and
STE11 kinases [53]. STE11 was known from genetic analyses
to be upstream of STE7 [53,54], and although evidence was
then lacking that STE11 acted directly on STE7, the knowledge
that MAP2K1 was itself regulated by Ser/Thr phosphorylation,
together with the parallels between FUS3/KSS1 and ERK1/
ERK2 and STE7 and MAP2K1, both in primary structure and in
their regulatory relationship, led to an expectation that STE11
acted directly on STE7 and a mammalian STE11 homologue
would prove to be the physiologic activator of MAP2K1/2
downstream of the RTKs. The yeast mating pathway however is
regulated by a GPCR [55]; yeast do not contain receptor- or
nonreceptor-tyrosine-specific protein kinases [56]. Yeast also
lack orthologs of Raf kinases, and a role for Raf actingMAPK MAPKAPKS
/2 ERK1/2 Rsks (1–4) MNKs MSKs
/7 JNK1/SAPKγ JNK2/SAPKα
JNK3/SAPKβ
/6 P38a,β P38γ,δ MAPKAPK2,3,5 MNKs MSKs
ERK5
1152 J. Avruch / Biochimica et Biophysica Acta 1773 (2007) 1150–1160downstream of receptor tyrosine kinases had been established
by genetic analyses of receptor tyrosine kinase signaling in the
metazoans, C. elegans and D. melanogaster (reviewed in
[57,58]). The finding that NIH3T3 cells transformed by a vRaf
oncogene exhibited a constitutive activation of endogenous
MAP2K raised the possibility that the vRaf (Ser/Thr) kinase
itself might act directly on MAP2K; in fact the cRaf1 kinase
catalyzed the in vitro phosphorylation and robust activation of
MAP2K [59], a finding rapidly confirmed [60,61].
Drosophila and C. elegans have only one Raf ortholog, and
genetic evidence ultimately established that the Raf kinase is the
only MAP3K recruited by receptor tyrosine kinases for
activation of the ERK pathway. Other essential components of
RTK signaling revealed through fly and worm genetics included
the Ras GTPase, its guanyl nucleotide exchange factor (SOS)
and the SH2/SH3 domain adaptor protein Sem5/DRK, the
worm/fly homolog of the mammalian Grb2 polypeptide
[57,58]. The latter was found to be constitutively associated
with SOS and the complex was recruited to the membrane by
Grb2-mediated binding to the activated, tyrosine phosphory-
lated RTK, thereby promoting Ras GTP charging [62]. Avariety
of transfection and microinjection studies in mammalian and
Xenopus cells had demonstrated that RTK activation of the
MAPK required active Ras, and that Ras-GTP itself is able to
activate the MAPK pathway (e.g., [63–69]). The subsequent
finding that Raf binds selectively to the GTP loaded form of Ras
([70–75]; reviewed in [76]) thus uncovered the last of the
central biochemical steps in RTK activation of the MAPK
pathway. These discoveries provided the first understanding of
the physiologic functions and biochemical mechanisms of
cellular protooncogenes that, in mutant form contribute with
high frequency to human cancers. In addition, the demonstra-
tion that Ras, through its switch1 loop, a segment whose
configuration was shown previously to be GTP-dependent,
binds in a GTP-dependent manner to a specific, structurally
conserved domain in the cRaf-1 aminoterminal noncatalytic
segment, thereby recruiting cRaf-1 to the membrane and
initiating its activation, established a paradigm for the
biochemical mechanism of action of the vast majority of all
small GTPases.
3. A favored architecture for signal transduction
The discoveries that unveiled the MAPK pathway and its
regulation by receptor tyrosine kinases (RTK) were exciting
because of their rapid convergence from studies on evolutio-
narily distant systems, providing a forceful demonstration that
evolution conserves not only critical housekeeping molecules,
but useful regulatory modules and designs as well. Never-
theless, the description of RTK regulation of the MAPK
pathway proved to be only the opening act in the MAPK story.
Protein kinases other than Raf capable of activating MAP2K1
and 2 were soon identified; thus the cMos protein kinase was
shown to be the physiologic MAP3K operating in the meiotic
maturation of Xenopus oocytes [77–79]; somewhat later, the
COT/Tpl-2 protooncogene was shown to act as a physiologic
activator of MAP2K1 or 2 in response to lipopolysaccharideacting through toll receptors [80]. The discovery in both S.
cerevisiae and S. pombe of MAP3K/MAP2K/MAPK cassettes
distinct from that of their mating pathways (reviewed in [81])
foretold the discovery of additional MAPK pathways in
metazoans. Thus independently and contemporaneously, the
SAPK/Jnk [82,83] and the p38 [84–87] subfamilies of
mammalian MAPKs were discovered through a variety of
independent approaches, and ERK5 slightly later [88]. Each of
these newer MAPK subfamilies was shown to be regulated by
distinct MAP2Ks; MAP2K4/7 for the SAPK/Jnks, MAP2K3
for p38αβ whereas MAP2K6 activates all four p38s (reviewed
in [89]) and MAP2K5 for ERK5 [88]. MAPK activation in each
of these cassettes is achieved by MAP2K-catalyzed phosphor-
ylation of the ThrXaaTyr motifs in the MAPK activation loop;
ERK3, which lacks this motif, remains somewhat an enigma
[90,91]. Most unexpectedly, a plethora of MAP3Ks emerged
[92–98], reflecting the exceptional variety of signals capable of
recruiting these pathways, usually in combinatorial arrays. The
model established by the Ras regulation of Raf was soon
extended by the discovery that members of the Rho subfamily
of GTPases, especially cdc42 and rac1 regulate the SAPK/Jnk
and p38 pathways [99–103] acting at the level of the MAP3Ks
of the MLK subfamily. Although the SAPK/Jnk and p38
pathways were initially characterized by their seemingly
preferential activation by cellular stresses and inflammatory
cytokines [104], this distinction from the insulin-mitogen
activated MAPK pathway has become progressively blurred,
as it is now evident that there is tremendous tissue- and
developmentally-specific variation in the upstream input to each
of these three MAPK subfamilies.
Once the basic architecture of these pathways and the
identity of the core components had been accomplished, it
became feasible to ask about the crucial determinants of
pathway activation and substrate selection. The dominant
multifunctional effector of the MAP3K/MAP2K/MAPK cas-
sette is the MAPK element. It became evident early that for the
RTK input, the intensity and duration of the stimulatory input
upstream of the MAP3K/MAP2K/MAPK cassette, as con-
trolled e.g., by receptor density, exerted a profound impact on
the cell fate chosen, by altering the duration of MAPK
activation and thus the likelihood of nuclear entry and access
to nuclear targets ([105]; reviewed in [106,107]).
4. MAPKs have a broad reach in cell regulation
The wide reach of these pathways in cell regulation emerged
with the discovery of candidate MAPK substrates. Thus,
prominent among MAPK substrates are other multi-target
signal transduction proteins, most notably numerous transcrip-
tional regulatory proteins and several other protein kinases.
Notable among the early examples of transcriptional targets
were a number of nuclear protooncogenes, e.g., cJun [108],
cMyc [109] and p62TCF/Elk1 [110] as well as ATF2 [111],
MEF2C [112]. The protein Ser/Thr kinases that are regulated by
the various MAPKs include the Rsk1–4 (by ERK1/2)
[113,114], MAPKAP kinases (MK2,3:p38α/β;MK5:p38β/
ERK3) [115,116], MSK1,2(by ERK1/2, p38α/β) [117–119]
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kinases, collectively referred to as MAPK-Activated Protein
Kinases (MAPKAPKs), are themselves multifunctional regula-
tors with a wide variety of targets, including many transcrip-
tional regulatory proteins and a few translational regulators.
Importantly however, the MAPKAPKs have a radically
different substrate specificity than their upstream controlling
MAPK, and this diversification of substrate specificity confers
tremendous reach as to the targets whose phosphorylation is
ultimately under the control of a MAPK. Early work established
that the classic MAPKs (ERK1,2,SAPK/Jnks,p38s) are each,
like the cdks, “proline-directed” kinases [109,123,124]; the Ser/
Thr residues they phosphorylate is always directly aminoterm-
inal to a Pro. This Ser/ThrPro motif constitutes a negative
determinant for kinases of the AGC and CAMK class [125].
The MK, MSK and MNK subfamilies are in the CAMK group
of the human kinome and thus share general specificity of that
class for substrates with an Arg situated at −3 [126]. The Rsks
each encompass two catalytic domains, a carboxyterminal
CAMK-related domain which is the primary target of the
MAPK, but whose function is exclusively devoted to activation
of aminoterminal AGC-related catalytic domain (acting in
concert with PDK1); only the aminoterminal domain is active
toward exogenous substrates [114], with a preference for Arg at
−3 and −5. The ability of ERK1/2 and p38α/β to control AGC
and CAM kinases allows these MAPKs to control the
phosphorylation of many of the same substrates/sites that are
regulated by the cyclic nucleotide regulated kinases (AGC), the
Type 1 Ptd Ins lipid kinases (acting through the AGC subfamily
of PKBs), and the Ca++/DAG regulated kinases (AGC
subfamily of PKCs, CaMK1–4) [125]. A comprehensive
catalog of MAPK and MAPKAPK substrates is not available,
however a recent review [127] enumerated 160 well-documen-
ted substrates of ERK1/2 alone, suggesting that the total number
of proteins whose function is regulated by these protein kinases
is likely to exceed one thousand.
5. MAPK substrate selection
Early studies of MAPK specificity using synthetic peptide
substrates based on the sequence of myelin basic protein as well
as bona fide MAPK substrates clearly showed the requirement
for Pro [109,123], with ERK1/2 preferring the motif of
ProXaaSer/ThrPro surrounded by basic residues and SAPK/
Jnk preferring Ser/ThrPro in a more acidic context [128].
Nevertheless, the peptide substrates exhibited very high Kms
(e.g., 200–300 μM) as compared to the native polypeptide
substrates, suggesting that the proline directed specificity of the
MAPKs should be viewed as a qualifying feature of substrate
selection, rather than as a determinant. These results were
radically different than had been observed in the analysis of the
specificity of PKA, wherein short synthetic peptides based on
the amino acid sequence surrounding a substrate phosphoryla-
tion site e.g., of pyruvate kinase [129,130], or denatured
pyruvate kinase [131] were phosphorylated with Kms
(∼10 μM) approaching those observed for the native protein,
suggesting that the major determinants of PKA substrateselection were located very close in the primary sequence to
the phosphorylation site. The low affinity of peptides based on
MAPK phosphorylation sites, and the adverse effects of
substrate denaturation strongly suggested that the major
determinants of MAPK substrate selection were located in
segments of the primary sequence that were remote from the
phosphorylation site in primary sequence and perhaps con-
formationally determined. The validity of this inference was
first established for the SAPK/Jnk catalyzed phosphorylation of
cJun, where a segment in the cJun aminoterminus (the delta
domain, AA31–47, deleted in vJun) acts as a high affinity
binding site for the kinase, which phosphorylates SerPro sites at
AA63 and 73 [82,132,133]. Subsequent studies revealed
docking sites in many substrates of each of the three canonical
MAPK families usually called the D domain, whose general
features include a cluster of basic residues upstream of an LXL
motif ([K/R]2–3-X1–6-[L/I]-X-[L/I]), occasionally with an addi-
tional cluster of hydrophobic residues further carboxyterminal
[134–136]. In a substrate such as SAP-1 that is shared by
ERK1/2 and p38, systematic mutagenesis can identify residues
that preferentially affect phosphorylation by either kinase [134].
Nevertheless, simple swapping of specificity by swapping D-
domains is only occasionally successful, suggesting that
multiple factors contribute to docking including weaker
interactions near the phosphorylation site and elsewhere, the
latter dependent on overall conformation. The D domain can be
situated on either side of the Ser/ThrPro; in some substrates
other than the downstream kinases, mostly transcription factors,
a PheXaaPhe(Pro) (called “docking site for ERK, FXF” or DEF
domain) is sometimes found on the carboxyterminal side of
phosphorylation site, located much closer in primary sequence
to the Ser/ThrPro than is the D domain (reviewed in [135,136]).
Functional PheXaaPhe(Pro) docking motifs are sometimes
found in the absence of the common, basic-hydrophobic
motif, as in cFos [137]; when both a D domain and a DEF
motif are present, they may direct the phosphorylation at the
same or different sites. The ERK1 and 2/p38 downstream
kinases MNK and MSK as well as several other substrates
contain the docking motif LeuXaaXaaArgArg [136]. Docking
site motifs have not been identified in all candidate MAPK
substrates, so that the possibility remains that additional motifs
remain to be discovered, or that intermediating proteins, i.e.,
“scaffolds”, some of which contain D domains, act to confer
specificity, as occurs with PKA and the AKAPs [138,139].
Docking sites are well described for protein kinases other than
the MAP kinases [140] and the relative contributions of docking
versus phosphorylation site sequence to the determination of
protein kinase specificity is under continued study [141].
6. Docking motifs critical to pathway regulation
6.1. Docking on the MAPKs-
Docking motifs similar to the D domain on the MAPK
substrates have also been identified in the majority of MAPK
regulatory proteins, i.e., the MAP2Ks, the dual specificity
MAPK phosphatases (MKPs) and certain scaffold proteins
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common region(s) on the MAPK.
The first such MAPK region (the “common docking” or CD
domain) was that defined on the large lobe of the SAPK/Jnk
catalytic domain [142]. CD domains, now defined on all three
major classes of MAPK, contain several acidic residues that
presumably interact with the Arg/Lys of the substrate D domain.
In addition, the LeuXaaLeu motif in the D domain binds to
hydrophobic residues in the conserved kinase core of p38α
located within a groove formed between β7–β8 and αD-αE
loop regions [143]. The PheXaaPhePro/DEF motif binds to a
pocket formed by the P+1 site, αF helix and the MAP kinase
insert segment that is occluded by the unphosphorylated
activation loop and thus available to substrates only after
MAPK activation [144]. An additional region on the kinase
catalytic domain conferring specificity, the ED site, was first
detected as a pair of acidic residues in p38 that contribute to p38
binding to its specific substrates MK2 and MK5. The cor-
responding sequence in ERK2 is ThrThr; replacement by
GluAsp confers on ERK2 the ability to bind MK2 and enhances
its ability to activate MK2 in vivo [145]. The CD domain and
ED site are not close in primary sequence but are nearby on the
surface and define a surface groove that mediates MAPK
binding not only to substrates, but to all partners. Thus at least
three separate regions on the MAPK catalytic domain surface,
distinct from the catalytic site, have been identified as
conferring specific interaction with MAPK partners. This
number may well increase as more substrates are identified.
6.2. Docking on the MAP2Ks-
The MAP2Ks are the chokepoint in the pathway, inasmuch
as they funnel the upstream input from numerous MAP3Ks into
a very limited number of MAPKs. Thus MAP2K1/2 phosphor-
ylates ERK1/2, MAP2K4/7 the SAPK/Jnks (although some
input of MAP2K4 into p38 also occurs), MAP2K3 acts on
p38αβ and MAP2K6 all p38 isoforms, and MAP2K5 on ERK5.
MAP2K1,2,3,4,6,7 contain one or more (e.g., MAP2K7) D
domains onto which the MAPKs dock [146]. The MAP2K D
domains are uniformly situated aminoterminal to the MAP2K
catalytic domain, although the MAP2K2 D domain has been
shown to function effectively if moved to the carboxyterminal
side of the catalytic domain [147]. MEK5 does not contain a D-
site but instead contains a novel MAPK-docking site of acidic
character [148]. The MAP2K D site is critical for efficient
MAPK activation in mammalian cells however, the binding of
MAP2Ks to MAPKs parallels the pattern of MAP2K-catalyzed
phosphorylation only roughly. Thus, the D domains of
MAP2K1/2 do not bind SAPKα/Jnk2 effectively, however
replacement of the MAP2K2 D domain by that from the ERK1/
2 substrate ets1, or by the D domain from STE7 enables
effective MAP2K2 activation of ERK1/2 [147]. Thus the main
functions of the D domain appear to be in providing a high local
substrate concentration to the MAP2K and in cytoplasmic
tethering of the inactive MAPK (the MAP2Ks are constitutively
cytoplasmic). Importantly, MAPK activation is accompanied by
dissociation from the MAP2K, freeing the MAPK to interactwith its substrates, with the MKPs [149–151] and when ac-
tivation is sustained, enabling the cytoplasmic MAPK to cycle
rapidly through the nucleus and achieve a high activity in that
compartment [105–107].
MAP2Ks can also interact stably with their upstream
regulators, the MAP3Ks. The first example was provided by
the Pbs2p kinase, the MAP2K in the S. cerevisiae osmosensing
pathway [152]. Pbs2 binds the MAP3K, STE11 as well as the
MAPK, Hog1; upon exposure to hyperosmolarity Pbs2p is
recruited by its proline-rich motif to the cytoplasmic SH3
domain of the membrane osmosensor Sho1p, enabling STE11
to be phosphorylated and activated by the membrane associated
STE20p kinase [153]. Pbs2p, through another segment
aminoterminal to its catalytic domain also binds the MAP3Ks,
Ssk2/22; the latter are activated by a two-component histidine
kinase osmosensor, Sln1 (via the relays Ypd1/Ssk1), and
activate Pbs2p entirely separate from STE11 [154]. Recently,
a docking motif on the MAP2K1,3,4,6,7 utilized for many
MAP3Ks has been identified, located at the carboxyterminal
end of the catalytic domain extending beyond the catalytic core
[155]. This MAP2K segment, called the DVD site (domain for
versatile docking), contributes detectably to the specificity of
individual MAP3Ks for the MAP2K, however DVD site
swapping studies indicate that additional determinants on the
MAP2Ks remain to be elucidated. The SAPK/Jnk and p38
pathways are usually activated in tandem, so it is not surprising
that many of the MAP3Ks that activate MAP2K4/7 also activate
MAP2K3/6; the overlapping specificity of the DVD sites on
those MAP2Ks for various MAP3Ks probably accounts, at least
in part, for this sharing; in contrast, the MAP2K1 DVD site
binds Raf but not other classes of MAP3Ks. The DVD site
appears to interact with the small lobe of the MAP3K catalytic
domain, but as with the MAP2Ks, other MAP3K segments are
also important for the MAP3K/MAP2K association. It may be
at this level of the cassette that scaffold proteins make their
greatest contribution.
7. An abundance of MAP3Ks and MAP4Ks
The MAP3Ks are the most numerous of the core kinase
elements. The challenge is in defining the specific upstream
inputs and cellular functions mediated by each. It appears likely,
based on the phenotypes of several murine MAP3K gene
deletion models, that whatever functional overlap exists, each
MAP3K utilizes the same core MAP2K/MAPK module to
execute at least some distinct signaling events. The three
members of the Raf family only mediate the activation of
MAP2K1/2 and underlie ERK1/2 activation in the vast majority
of examples adduced thus far. Inactivation of the murine cRaf-1
[156] and Braf [157] genes each results in embryonic lethality;
nevertheless, the phenotypes of the null embryos differ. Thus
Rafs are not redundant and their biologic outputs differ, at least
somewhat. Unexpectedly, a mutant form of cRaf-1 that lacks
MAP2K catalytic activity can overcome the susceptibility of the
murine cRaf-1(−/−) cells to apoptosis, demonstrating that
ERK1/2 activation does not fully explain the biologic role of
cRaf-1 [158]. Thus, although cRaf-1 is undeniably an active
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purely as a scaffold [159,160], independent of its catalytic
activity. Interestingly, this is the dominant (probably sole)
phenotype of the KSRs, the kinase subfamily most closely
related in primary sequence to the Rafs.
The diversity of MAP3Ks that participate in regulation of the
SAPK/Jnk and p38 pathways is especially striking, but it is clear
that the MAP3Ks in this pathway are highly specialized; e.g.,
MEKK1, 2 and 3 each activate the SAPK/Jnk pathway, but
inactivation of those genes results in entirely distinct patterns of
gene expression [161]. This diversity of MAP3K function may
in part be due to differing patterns of tissue-specific expression
or to MAP3K targets other than the MAP2Ks, as well as to
differences in the composition of the multicomponent MAP2K/
MAPK assemblies that are organized by the diverse noncata-
lytic segments of the MAP3Ks or by the associated noncatalytic
scaffolding proteins. These factors override the structural
homology within the MAP3K subfamily catalytic domains to
enable differing subcellular localization and downstream
targets. In addition to the scaffolding functions of certain
MAP3Ks, e.g., MEKK1 (and noncatalytic proteins, see next),
the MAP4Ks may also play such a role. The vast majority of
MAP4Ks are from the large class of Ste20 protein kinases; Dan
et al. [162] have enumerated nearly 30 human Ste20-related
kinases, subdivided into ten classes. It is most convenient to
separate the PAKs, which have a carboxyterminal catalytic
domain, from the more numerous GC kinase-related polypep-
tides, which have an aminoterminal catalytic domain; all Ste20
subfamilies exhibit highly diverse noncatalytic segments.
Nearly all of the Ste20-related kinases tested can act as
upstream regulators of the MAP3Ks, either serving in a
noncatalytic mode as a scaffold to promote pathway assembly
and MAP3K autoactivation, or additionally as a catalyst to
phosphorylate and transactivate the MAP2K. Moreover, it is
clear that the outputs of essentially all the Ste20/MAP4Ks are
much broader than control of MAPK pathways [163].
8. Noncatalytic scaffolds for the MAPK pathway
The first noncatalytic MAPK pathway scaffold identified
was the STE5p protein of the S. cerevisiae pheromone mating
pathway [164–166]. Ste5 binds independently and concomi-
tantly STE11p, STE7p and the MAPKs, KSS1p and FUS3p and
is recruited to the membrane by its ability to bind the free Gβγ
subunits released upon engagement of the pheromone receptor;
once there, STE20p, activated by Cdc42, phosphorylates and
activates STE11p. Although docking sites are present in STE11
and STE7, inactivation of STE5 abolishes the mating response.
Thus the noncatalytic scaffold STE5 is essential for signal
transmission in the pheromone pathway. Although Ste5 may
participate actively in signal transmission [167], its essential
function appears to be as a tether, inasmuch as substitution of
heterologous binding sites permits effective function [168].
Vertebrate homologs of STE5 do not exist, however a variety of
noncatalytic polypeptides capable of binding two or more of the
core kinases have been identified for each of the three major
MAPK pathways (reviewed in [169–171]). The first identifiedwas the Drosophila KSR recovered as a kinase-like polypeptide
that acted as a suppressor of activated Ras. The KSR
polypeptides exhibit alterations at several conserved residues
in the kinase catalytic domain that are required for activity and
most reports detect no KSR-specific catalytic activity [169].
Nevertheless, some reports describe KSR kinase activity
[172], but inasmuch as KSR can bind constitutively with
MAP2K1 and can interact, stably or transiently, with several
other protein kinases (in addition to cRaf-1 and ERK1/2), the
ability of KSR to catalyze phosphorylation remains unproven.
KSR is one of the first and among the best studied of the
“pseudokinases”, which constitute approximately 10% of the
518 members of the human kinome [173]. KSR is recruited to
the membrane upon Ras activation, where it interacts with
Raf, and Ras controls KSR turnover through the ubiquitin
ligase, IMP [174]. KSR(−/−) mice are normal, but subtle
abnormalities of ERK1/2 activation can be detected, e.g., in T
cells, and these animals are relatively resistant to ras-induced
tumorigenesis [175]. A reasonable conclusion is that KSR may
be necessary for optimal Ras activation of ERK1/2 in specific
settings, but unlike STE5, is not required for adequate
pathway performance. A considerable number of other
noncatalytic polypeptides have been described as stably
interacting with one or more elements of the Raf/MAP2-
K1or2/ERK1/2 cassette, including CNK, MP1, MORG1,
SUR-8, RKIP, sprouty/spred, and the beta arrestins (which
couple the cassette to several classes of GPCR); depletion or
overexpression of these elements results in phenotypes relating
to altered MAPK signaling [169–171]. Several of these
polypeptides exhibit multidomain structures and participate in
signaling through other pathways, in addition to their MAPK-
related outputs. Thus far, unlike STE5, few examples in
mammals are available wherein depletion of these noncatalytic
scaffolds in the ERK1/2 pathway results in dramatic
interference with physiologic pathway function. Many of the
“positively-acting” scaffolds may be dispensable for physio-
logic operation of the ERK1/2 cassette in the most settings,
but essential in a few specific responses, or in the infrequent
circumstances wherein maximal activity is required. Some of
these scaffolds may in addition participate in maintenance of
low basal pathway activity, yet their absence may be com-
pensated by ambient protein phosphatase activities.
Among the various noncatalytic scaffolds identified for the
SAPK/Jnk and p38 pathways [169], e.g., beta arrestin-2,
ABP280/filamin, IKAP, POSH, JIP1-4, etc. the phenotypes
seen with deletion of the murine JIP1 and 3 genes provide
excellent illustrations of the narrow, but important role of
scaffolds. JIP1-3 each interact with Jnk1-3, MAP2K7 and one
or more MAP3Ks of the MLK family, as well as with the light
chain of kinesin-1. The latter conveys JIP1 to synapses; JIP3 is
localized to neuronal cell bodies Deletion of the Jip3 gene
results in major defects in brain development culminating in
death at birth due to failure to breathe [176]. JIP1 deficient mice
have a much more subtle phenotype; they are viable and
phenotypically normal under usual conditions. Nevertheless, if
their CNS is subjected to excitotoxic or anoxic/ischemic stress,
a reduced activation of SAPK/Jnk is observed as compared to
1156 J. Avruch / Biochimica et Biophysica Acta 1773 (2007) 1150–1160wildtype mice, associated with reduced size of ischemic infarcts
[177]. JIP1, in addition to its expression in brain, is also
expressed at lower levels in adipose tissue and skeletal muscle.
JIP1 null mice exhibit diminished activation of Jnk1 in those
tissues in response to a high fat diet, accompanied by di-
minished phosphorylation of IRS1 at ser307 and improved
insulin responsiveness, as compared with wildtype mice fed
such diets [178]. These findings indicate that, with some
exceptions (e.g., JIP3), elucidation of the biologic roles of the
noncatalytic scaffolds will require sophisticated examination of
gene-deleted murine models stressed in a variety of ways.
9. Open questions
It has been known for some time that the frequency of
activating ras mutations in human cancers approaches 30%
[179]; this together with the essentiality of the ERK pathway for
ras-directed proliferation identified this pathway as a prime
target for anticancer therapies. The more recent discovery of
activating mutations in BRaf, especially in malignant melanoma
[180] added further impetus to the search for clinically useful
inhibitors of this pathway, and several agents directed toward
Raf and MAP2Ks are now in clinical trials [181,182]. The
important roles played by the SAPK/Jnk and p38 kinases in
response to a variety of cell intrinsic and extrinsic stressors
suggested strongly that these kinases are potentially important
therapeutic targets in a variety of inflammatory and degen-
erative diseases. Several inhibitors of these MAPKs or upstream
elements in these pathways have now entered clinical trials,
especially in Rheumatoid arthritis [183,184], and others are
planned for illnesses such as Crohn's disease and psoriasis.
Neurodegenerative conditions such as Parkinson's disease,
Alzheimer's disease, hearing loss and others [185,186] are other
areas of especial activity. Although specific pathway inhibitors
of undeniable clinical efficacy have yet to make an appearance,
optimism remains strong.
The development of specific inhibitors, along with gene
modification will certainly advance our understanding of the
biologic roles of the MAPK pathways in development, and in
adult physiology. Biochemical problems that occupy consider-
able effort include the identification of additional substrates and
the mechanisms of substrate selection; the identification of all
components that regulate pathway activity, their mechanism and
specific impact on the pathway output under physiologic
conditions; the mechanisms that control the subcellular
localization of pathway components and the significance for
pathway regulation; the biochemical mechanisms that control
pathway activation state and pathway cross-regulation. Work on
the roles of the MAPKs in plants has accelerated in recent years
[187–189]. Substantial gains remain to be made in these and
other areas.
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